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ABSTRACT
Objective: To compare the clinical characteristics and outcomes of HIV-1-HTLV-1 coinfected pa-
tients, in Bahia, Brazil. Methods: Retrospective, comparative study. Results: Among a total of 123 
consecutive HIV infected patients, 20 men (20.6%) and 6 women (23.1%) had detectable an-
tibodies against HTLV-I/II. The major risk factor associated with coinfection by HTLV was in-
travenous drug use (57.7% of coinfected patient versus 9.2% of HTLV seronegative patients, 
p < 0.0001). Coinfected patients had higher absolute lymphocyte counts (1,921 + 762 versus 
1,587 + 951, p = 0.03). Both groups of patients had similar means of CD4+ and CD8+ cell counts. 
However, among patients with AIDS CD4+ cell counts were signifi cantly higher among those coin-
fected with HTLV-I/II (292 ± 92 cells/mm3, versus 140 ± 177cells/mm3, p = 0.36). The frequency and 
type of opportunistic infections were similar for both groups, but strongyloidiasis and encephalopa-
thy were more frequently diagnosed in coinfected patients (p < 0.05). On the other hand, patients 
coinfected with HTLV-I/II received signifi cantly less antiretroviral therapy than singly infected by 
HIV-1. Conclusion: Coinfection by HTLV-I/II is associated with an increased risk of strongyloidiasis 
for HIV patients. Higher CD4 count may lead to underestimation of immunodefi ciency, and delay 
to initiate antiretroviral therapy. 
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INTRODUCTION
The human immunodefi ciency virus type-I 
(HIV-1) is the causative agent of the acquired 
immunodeficiency syndrome (AIDS). Hu-
man T-cell leukemia/lymphoma virus type I 
(HTLV-I) is conclusively associated with adult 
T-cell leukemia/lymphoma (ATLL), and tropical 
spastic paraparesis/HTVL-associated myelopa-
thy (TSP/HAM). The role of HTLV-II infection 
as a cause of disease is still controversial.1-5 These 
infectious agents all share a similar pattern of 
transmission. The established routes of infection 
are sexual, parenteral (blood transfusion, needle 
sharing or percutaneous exposure), and vertical 
(congenital or via breastfeeding).6-11 Coinfection 
with these two distinct retroviruses has been fre-
quently reported in the last few years.12-16
There is some evidence suggesting that double 
infection by HIV-HTLV may alter the clinical and 
laboratory course of AIDS, but the real impact of 
coinfection on clinical presentation and outcome 
of AIDS patients remains to be determined.17-19
Bahia, a northeastern state of Brazil, is 
an endemic area for HTLV infection. A re-
cent report showed a prevalence rate of 1.8% 
of HTLV-I/II antibodies among the general 
population.20 The reported incidence of AIDS 
cases in Salvador, the capital city of Bahia 
state, is 16.3/100,000 inhabitants.21 In a previ-
ous, cross-sectional study of 895 HIV-infected 
patients we detected a rate of coinfection by 
HTLV-I/II of 16.7%.16
This study was conducted in order to 
identify potential differences in the clini-
cal evolution of HIV infected patients with 
or without HTLV-I/II coinfection, as well 
as to ascertain the impact of coinfection 
on the surrogate markers of HIV infection. 
Since highly active antiretroviral therapy 
(HAART) has dramatically modified the 
natural course of HIV infection, we retro-
spectively evaluated patients diagnosed be-
fore the HAART era.
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MATERIAL AND METHODS
Patient population
A total of 123 consecutive patients seen at the AIDS clinics of the 
Hospital Universitário Prof. Edgard Santos, in Salvador, Brazil, dur-
ing the years of 1994 and 1995, were selected. To be eligible for the 
study, patients had to have a Western blot (WB)-confi rmed infec-
tion by HIV-1, a previous test for HTLV-I/II antibodies (or stored 
serum sample), and a follow-up period of more than 6 months. 
The period of time was chosen in order to evaluate the impact of 
coinfection among patients before triple antiretroviral therapy 
was introduced as the standard of care for Brazilian patients 
with AIDS. Information on age, gender, route of transmission of 
retroviral infection, date of diagnosis, and clinical stage, both at 
the time of diagnosis and at the fi nal evaluation were obtained 
from medical records or directly from the physicians responsi-
ble for the patients care. Clinical course, including the frequency 
and type of opportunistic infections (OI) or malignancies, use 
of antiretroviral drugs, the duration of therapy, and duration of 
follow-up was also recorded. The 1993’s CDC revised classifi ca-
tion was used for disease staging. All data were retrospectively 
collected from patients’ medical charts.
Laboratory data used for comparison between the two 
groups were CD4 and CD8 cell counts, hemoglobin levels, and 
absolute number of lymphocytes. Two independent reviewers, 
who were blinded to the results of HTLV-I/II serology, per-
formed data collection.
Serology tests
Screening for HIV-1 antibodies was performed by EIA (Genetic 
Systems, Seattle, WA) and confi rmed by WB (Cambridge-Bio-
tech, Rockville-MD). Antibodies against HTLV-I/II were detect-
ed using an EIA kit (Coulter Corporation, Hialeah, FL), and con-
fi rmed with WB (Fujirebio, Tokyo, Japan). The reactive samples 
(presence of any band on WB) were then retested with a synthet-
ic peptide-based ELISA (Coulter Select - Coulter Corporation) 
and by a WB (Diagnostics Biotechnology, Singapore) containing 
envelope recombinant proteins (rgp46-I and rgp46-II), which al-
lows for the discrimination between HTLV-I and II infection.22-24
Statistical analysis
Descriptive statistics were calculated and proportions were com-
pared by calculating odds ratio (OR) and estimating 95% con-
fi dence intervals (CI) by the Cornfi eld method. Yates-corrected 
chi-square analysis was used to measure associations and cal-
culate 2-tailed P values. Means were compared using Student’s 
t test, and the Kruskal-Wallis test, when applicable. All calcula-
tions were performed by using EPIINFO 6.01b.
RESULTS
Medical records were reviewed for 123 patients (97 male), 
who fulfi lled the inclusion criteria for the study. Twenty men 
(20.6%) and 6 women (23.1%) had detectable antibodies 
against HTLV-I/II (Table 1). Median follow-up time was 16 
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Table 1. Frequency of episodes of diagnosed infections according to the serological status for HTLV-I/II infection
                            Infection HTLV serology
  Negative HTLV-I HTLV-II P value*
P. jiroveci pneumonia 20 1 1 0.3
CNS toxoplasmosis 14 5 - 0.8
Oral candidiasis 146 15 1 0.2
Esophageal candidiasis 17 1 1 0.4
Tuberculosis 37 10 1 0.8
Strongyloidiasis 2 3 1 0.04
CNS cryptococosis 2 0 1 0.8
Recurrent herpes 31 2 1 0.4
CMV 10 2 0 0.9
Kaposi’s sarcoma 9 1 0 0.8
Bacterial infections 119 26 1 0.3
Cryptosporidiasis 6 0 0 0.6
Isosporiasis 4 1 0 0.9
Diarrhea 178 25 5 0.3
Peripheral neuropathy 5 2 0 0.8
Herpes zoster 12 4 1 0.8
Encephalopathy 1 2 0 0.04
*P value comparing negative and positive patients for HTLV-I/II antibodies. 
8Table 3. Risk factors for acquisition of retroviral 
infection among singly and dually infected patients
Risk factors Negative HTLV-I HTLV-II HTLV-I/II P  
      value*
Blood 0.5 0.1 0.1 0.1 0.4
transfusion
IVDU  0.9 12 0.3 - < 0.0001
Homosexual 45 10 - - 0.2
activity
Previous STD 29 08 0.2 - 0.7
Sex with 0.2 0.1 - - 0.9
prostitutes
None of the  10 - - NS
above
IVDU, intravenous drugs user; STD, sexually transmitted 
diseases; NS, nonsignificant.
*P value comparing negative and positive patients for HTLV-I/
II antibodies. The total may exceed the sample size, due to 
positive history for more than one risks in the list. 
months (range 6-56 months). The mean age was signifi -
cantly higher for men as compared to women (34.5 ± 8.1 
and 29 ± 8.8 respectively, P = 0.002) but there was no dif-
ference between the mean age for HTLV-positive and nega-
tive patients (Table 2). 
Risk factors for coinfection: the major risk factor asso-
ciated with coinfection by HTLV was intravenous drug use 
(IVDU). Among HTLV seropositive patients, 57.7% had a 
history of IVDU as the risk behavior for acquiring retrovi-
ral infections, compared to 9.2% among patients without 
HTLV coinfection (P < 0.0001). Infection by HTLV-I/II 
was not associated with blood transfusion, sexually trans-
mitted diseases (STD), or sexual behavior (Table 3).
Clinical characteristics: at the time of the first visit to 
the clinic, 73 (59.3%) patients were asymptomatic, while 
the remaining 50 patients had an established diagnosis of 
AIDS (category C by CDC criteria). The frequency of epi-
sodes of OI diagnosed during follow-up were compared 
according to the serological results for HTLV-I/II infec-
tion: there was no difference in the overall frequency of 
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Table 2. Mean age and gender distribution for HIV-1 infected patients according to their serology results for 
HTLV-I and HTLV-II
                              HTLV serology results 
   Negative HTLV-I HTLV-II HTLV-I/II P value
Age (mean ± sd) 33.2 ± 8.8 33.5 ± 7.4 35.5 ± 11.1 33 0.9
Gender     
 Male 77 (79%) 17 (81%) 0.3 (75%) 0 0.3
 Female 20 (21%) 4 (19%) 0.1 (25%) 1(100%) 
Total 97 21 04 01 
OI for both groups, but strongyloidiasis was diagnosed 
in 4/26 coinfected, compared to 2/97 in singly infected 
patients (OR = 8.55; 95% CI: 1.21-73.62, P = 0.02, Fisher 
exact test). In addition, two episodes of encephalopathy 
were diagnosed during the study period in HTLV-posi-
tive, but no case was detected among singly infected pa-
tients (P = 0.04, Fisher exact test). 
Laboratories results
Hemoglobin levels were similar for both singly (11.9 ± 
2.2 g/dL) and doubly infected (12 ± 2.3 g/dL) patients 
(P > 0.05).
Patients coinfected by HTLV-I/II had absolute lym-
phocytes counts significantly higher than those in-
fected by HIV-1 alone (1,921 ± 762 versus 1,587 ± 951, 
P = 0.03). However, when they were stratified by clini-
cal status, asymptomatic patients presented a similar 
number of lymphocytes, regardless of their HTLV-I/II 
serology status, while coinfected, symptomatic patients, 
had significantly higher lymphocyte counts (887 ± 
515 cells/mm3 versus 1,687 ± 731 cells/mm3, P = 0.02, 
Kruskal-Wallis test).
A total of 75 patients had at least one available CD4 
and CD8 counts. Mean CD4 and CD8 cells counts were 
similar in both groups of patients(P = 0.07, and P = 0.4 
for each mean count, respectively, Kruskal-Wallis test). 
However, coinfected patients diagnosed with AIDS at the 
time of their first visit had a mean CD4 count (292 ± 92 
cells/mm3 versus 149 ± 178 cells/mm3, P = 0.03, Kruskal-
Wallis test), absolute lymphocyte counts significantly 
higher. Coinfected patients who developed AIDS dur-
ing follow-up also had higher baseline CD4 count (679 
± 247 cells/mm3), than singly infected patients (303 ± 
249 cells/mm3; P = 0.07, Kruskal-Wallis test). This dif-
ference was not observed for patients who remained 
asymptomatic throughout the study period (525 ± 
270 cells/mm3 versus 532 ± 261 cells/mm3 for HTLV nega-
tive and positive patients respectively P = 0.9, Kruskal-
Wallis test). Since the study included patients followed 
before viral load tests were available, this information was 
not analyzed. Table 4 summarizes the laboratory results.
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Table 4. CD4+, CD8+ and lymphocyte counts (mean ± SD) of patients according to their HTLV serology 
Laboratory                                          HTLV serology 
Values/clinical  Negative HTLV-I HTLV-II HTLV-I/II P value*
Status n 102 25 0.4 0.1 
Symptomatic 50     
 CD4 cell counts 25 140 ± 177 292 ± 92 - - 0.036
 CD8 cell counts 25 695 ± 403 839 ± 537 - - 0.6
 Lymphocytes 50 887 ± 515 1,687 ± 731 - - 0.02
Asymptomatic* 73     
 CD4 cell counts 50 434 ± 281 537 ± 269 504 832 0.5
 CD8 cell counts 50 1,300 ± 883 797 ± 308 465 1,965 0.1
 Absolute lymphocyte count 72 2,013 ± 912 2,257 ± 835 1,845 ± 630 2,255 0.8
All patients 123     
 CD4 cell counts 75 334 ± 284 432 ± 237 504 832 0.2
 CD8 cell counts 75 1,112 ± 813 810 ± 339 465 1,965 0.2
 Absolute lymphocyte count 123 1,563 ± 952 958 ± 816 1,638 ± 490 2,255 0.1
P values were calculated by Kruskal-Wallis test, and compare HTLV I/II negative and positive patients.
*Only 50 patients had available CD4 cell counts.
Progression to clinical disease during the follow-
up period was similar for singly and coinfected pa-
tients (24/60 and 3/13, respectively, RR = 0.58; CI 0.20 
- 1.63 P = 0.3). Use of antiretroviral drugs was more fre-
quent among patients infected by HIV-1 alone (64.3%) 
compared to those coinfected by HTLV-I/II (42.3%) 
(P = 0.04, Yates corrected). This difference was more 
evident when we analyzed patients without a clini-
cal picture of AIDS (non-category C disease): only 
16.4% of coinfected patients were on antiretroviral 
therapy, in contrast to 51% of singly infected patients 
(RR = 0.23; 95% CI: 0.06-0.97 P = 0.04, Yates corrected).
DISCUSSION
Chronic infection by HIV is associated with immunodefi -
ciency, caused by progressive CD4 lymphocyte depletion. 
Infection by HTLV-I may also be related to some degree 
of perturbation of the immune response among patients 
that harbor the virus, but usually do not exhibit clinical 
symptoms.25
While there is evidence suggesting that coinfection by 
HIV-HTLV viruses may modify the clinical and laboratory 
fi ndings during the course of HIV infection, the lack of 
conclusive studies leaves the clinical impact of HTLV in-
fection on HIV infected patients open to controversy. The 
present report provides additional support for the conten-
tion that patients harboring HIV and HTLV may present 
a modifi ed clinical course of the HIV infection, character-
ized by a higher frequency of some clinical events.
The demographic characteristics for singly and dou-
bly infected patients were comparable in this report. In 
contrast, a previous, larger study, detected a higher preva-
lence of HTLV-I coinfection among women, in Bahia.26 
This discrepancy may be due to the smaller sample size 
of this work, which probably lacked sufficient power to 
detect differences in coinfection rates by gender (only 
6 women were coinfected).
Surrogate markers for HIV infection showed a distinct 
pattern for singly and doubly-infected patients. The ab-
solute lymphocyte counts were quite different in the two 
groups, with higher counts among HTLV coinfected pa-
tients. Similar number of lymphocytes in asymptomatic 
patients in both groups suggests that lymphocyte depletion 
occurs more slowly in coinfected patients during the course 
of HIV infection.
The analysis of CD4 cell count provided a similar pic-
ture. Asymptomatic patients had comparable counts of 
CD4 cells, but in contrats it was higher among coinfected 
patients presenting with clinical disease. CD8 cell counts 
were not related to the status HTLV infection, regardless 
of the patient’s clinical status. Similarly, hemoglobin levels 
were comparable in both groups.
The frequency of S. stercoralis OI was signifi cantly higher 
among coinfected patients, as it was for encephalitis with-
out other identifi able etiology. Infection by HTLV-I has 
been associated with higher risk for S. stercoralis parasit-
ism in HIV-negative patients..27-30 In a previous report, we 
also detected higher prevalence of S. stercoralis infection in 
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HIV-positive patients, compared to seronegatives.31 The pre-
sent report provides evidence that this association in HIV- 
HTLV coinfected patients is even higher than in HIV-1 singly-
infected individuals.
The association between coinfection and encephalopa-
thy is less clear: HTLV-I infection is associated with TSP/
HAM, a clinical entity characterized by signs and symp-
toms of myelopathy, but displaying some evidence of brain 
involvement, such as perivascular infi ltrates, demyeliniza-
tion, and white matter destruction. In addition, other se-
vere involvement of central nervous system has been re-
ported.32-35 Unfortunately, the retrospective design of the 
present study did not allow to clarify the exact cause of 
death of these two patients.
The rate of clinical evolution from asymptomatic infec-
tion to AIDS during the follow-up period was similar for 
both groups. However, the use of antiretroviral drugs was 
more frequent among singly-infected patients suggesting 
that the abnormalities in the number of lymphocytes and 
the CD4+ count induced by HTLV coinfection may de-
lay the initiation of antiretroviral therapy in coinfected pa-
tients, as predicted by Schechter et al. in a previous report.15 
Since CD4 cell count is still the main marker to defi ne the 
best moment to start antiretroviral therapy and/or prophy-
laxis for OI, this fact may add a clinically relevant problem 
to physicians, when attending patients in endemic areas for 
these two agents. 
The fi nding that cell subsets count is similar among 
asymptomatic patients, but signifi cantly different among 
those with clinical symptoms suggests that the decrease in 
CD4 cell counts occurs later in the evolution of coinfected 
patients. Nonetheless, the higher CD4 cell counts do not pro-
vide any immunological benefi t. It is likely that immunolog-
ical changes secondary to the progression of HIV infection 
may also be affected, or may modify the lymphoproliferative 
response that usually follows HTLV infection. However, the 
mechanisms and intensity of such immune modifi cations 
are still unclear.
Finally, the extent to which HIV/HTLV coinfection 
modifies clinical outcomes of HIV infected patients re-
mains unclear. There are some evidence supporting the 
hypothesis that coinfection by these agents may modulate 
the clinical presentation of these individuals, with an in-
crease in the frequency of some parasitic diseases, and of 
severe forms of scabies.31,36 In addition, there are evidence 
supporting a potential impact of coinfection on survival, 
which was shorter for coinfected patients than for those 
infected by HIV-1 alone.37,38
Our study also presents some limitations, that could 
have influenced the results: first, the retrospective de-
sign may prevent definitive conclusions, although, since 
HAART is currently the standard of care for all patients in 
need of treatment we could not evaluate the impact of in-
creased CD4 cell counts on physicians’ decision on when 
to start therapy. On the other hand, the higher proportion 
of IVDU among coinfected patients could also be con-
founding factor of lower rate of antiretroviral treatment 
among coinfected patients. It could be true for asymp-
tomatic patients, but our data showed that even patients 
with a clinical picture of AIDS had decreased chance of 
receiving therapy, which could not be explained on the 
basis of patients’ risk behavior. It makes more sense to 
conclude that the discrepancy between CD4 cell count 
and clinical status was probably the factor that misled 
physicians in deciding the optimal time to start treat-
ment. In addition, we did not have information on how 
many patients had stools examination performed for 
S. stercoralis parasitism, but in AIDS patients such para-
site usually causes severe diarrhea and the stools exami-
nation routinely performed in these situations, making 
unlikely that a symptomatic patient not having had a 
proper diagnostic investigation. 
Our results confi rm previous studies reporting higher 
CD4 cell counts in coinfected patients, and suggest that such 
phenomenon may mislead physicians in the choice of the 
optimal time to start antiretroviral therapy.15,39 It can not be 
ruled out the delay in starting antiretroviral therapy as one 
of the potential explanation for the higher mortality detect-
ed among coinfected individuals caused by increased CD4 
cell counts, rather than a direct effect of HTLV-I on AIDS 
progression. The increased frequency of S. stercoralis infec-
tion and encephalopathy also indicates that coinfection may 
modify the course of HIV disease. However, the available 
data provide only limited evidence and defi nitive answers 
will require larger, prospective studies.
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